Thromboembolic disorders are still the leading causes of morbidity and mortality in developed societies. Therefore, prophylaxis and treatment of arterial and venous thrombosis are among the main therapeutic challenges nowadays. Simultaneous action on several targets involved in pathology of thrombosis offers potential advantages compared to existing drugs which were developed as selective modulators of single targets. The review focuses on dual inhibitors of coagulation enzymes, dual antiaggregatory compounds exerting their action on different combinations of platelet targets, as well as on anticoagulant/antiaggregatory compounds which interfere with at least one target involved in blood coagulation and at least one target engaged in the process leading to platelet aggregation.
Keywords: Anticoagulants, antiplatelet, antithrombotics, dual inhibitors, multitarget drugs, prophylaxis, anticoagulant/antiaggregatory compounds, haemostasis, antiplatelet activity, antiaggregatory drugs, calcium ions, coagulation factors, pharmacokineticproperties, predictable pharmacokinetics, thromboxane synthase
Rights & PermissionsPrintExport